This also reduces the number of finger pricks and insulin injections. Dr Sweta Budyal, consultant endocrinologist and ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Type 1 diabetes is often confused with Type 2 diabetes, but they are two different diseases. Type 1 diabetes is an autoimmune ...

PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

At the time, insulin cost about $1,000 a month. Insulin pump supplies cost about $1,200 every three months, and diabetic test ...

On World Diabetes Day, we explore life as a diabetic in Türkiye, from managing the condition to accessing care and highlight ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...